A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.

Abstract excerpt

New direct acting antiviral agents are revolutionising hepatitis C virus (HCV) treatment. However, to date limited clinical trial data exists for outcomes in genotype 4 (GT4) HCV patients. GT4 HCV is more common in Africa, the Middle East, and Asia, and limited data exists to date for outcomes in Europe. We report the first "real-life" sustained virological response (SVR) outcomes using pegylated interferon and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Coinfection
• Share to Drug Therapy, Combination